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Introduction: Fibrolamellar carcinoma (FLC) is a rare pathologically distinct primary liver cancer. Surgical
resection is the only treatment associated with prolonged survival. Trans-arterial embolization (TAE), which is a
recognised treatment for hepatocellular carcinoma has been used to treat FLC. We present a case and performed a
literature review of patients with FLC treated with TAE.
Case presentation: We present a 19-year old female with a large potentially resectable FLC which was initially
treated with trans-arterial chemo-embolization (TACE) with drug eluting beads. The TACE was followed by
surgical resection. Histology confirmed tumour necrosis related to the previous TACE.
Discussion & literature review: We identified seven case reports and one case series of TAE for FLC. TAE was either
used as a neo-adjuvant therapy to facilitate subsequent tumour resection or as a palliative treatment modality.
We propose an algorithm for the treatment of FLC that includes TAE.
Conclusion: The rarity of FLC and the paucity of data precludes establishing clear evidence-based standards of
care. We propose an algorithm for the treatment of FLC. The establishment of an international registry may
facilitate the collection of better quality evidence.

1. Introduction
Fibrolamellar carcinoma (FLC), first described by Edmondson in
1956, is a rare pathologically distinct primary liver cancer that occurs in
adolescents and young adults and is not associated with cirrhosis or
underlying liver disease [1]. Fibrolamellar carcinoma is histologically
characterised by large eosinophilic, hepatocyte-like polygonal cells,
with prominent nucleoli and pale inclusion bodies surrounded by
abundant fibrotic bands (lamellae) [1,2] and was initially described as a
variant of hepatocellular carcinoma (HCC). Genomic sequencing has
however shown clear molecular differences between FLC and HCC.
Fusion of the DNAJB1 and PRKACA genes due to a deletion on chro
mosome 19 which activates protein kinase A has been demonstrated in
FLC with a specificity of 100% [3]. There is less male predominance
(male/female ratio 1.7), than in HCC (male/female ratio 3.2) and a
number of studies have suggested that FLC has a better prognosis
compared to HCC [4].
For curative intent, surgical resection is the treatment of choice.

There are, however, a few reports of orthotopic liver transplantation for
patients with irresectable disease [5,6]. Data on systemic therapy for
FLC are sparse and the role of chemotherapy in the neo-adjuvant,
adjuvant and palliative settings remains unclear [7]. Similar to HCC,
FLC has predominantly an arterial supply which makes trans-arterial
embolisation (TAE) including bland embolisation, trans-arterial
chemo-embolisation (TACE) and trans-arterial radio-embolisation
(TARE) feasible. We report on a case and performed a literature review
of the use of TAE for FLC.
This case report has been reported according to the SCARE criteria
[8]. The literature review was conducted according to the PRISMA
guidelines [9] and registered in the PROSPERO register (ID:
CRD42020193665).
2. Presentation of case
A 19-year-old female presented to an HPB unit in an academic hos
pital with a one-month history of upper abdominal pain and
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Fig. 1. A) CT scan, coronal view, arterial phase: demonstrating a hypervascular tumour with areas of hypodensity. The arrow points to the area were the tumour
abuts the left hepatic artery. B) CT scan, axial view, portal venous phase: showing dimensions of tumour prior to TACE C) CT scan, axial view, portal venous phase:
showing decrease in size 3 months after the TACE.

Fig. 2. Low power magnification showed: A) Intravascular embolization material (*) with surrounding necrosis (arrow heads) but also viable tumour (arrows); B)
The tumour arranged as nests and acinar structures with intervening hyalinization; C) Large polygonal tumour cells with abundant eosinophilic cytoplasm.

unintentional weight loss (five kilograms over the preceding three
months). She had no history of previous medical conditions or surgical
interventions. She was a non-smoker and did not use alcohol. Her gen
eral examination was unremarkable. On abdominal examination a hard,
non-tender epigastric mass could be palpated. Laboratory examinations
showed a normal full blood count, normal liver function tests, positive
hepatitis B surface antibody in keeping with previous immunization,

negative hepatitis C and HIV serology and an AFP of 4.5 ku/L. An
abdominal and chest contrast-enhanced (CE) CT scan and MRI with
hepatocyte-specific contrast (Gd-EOB-DTPA, Primovist®, Bayer Scher
ing Pharma, Berlin, Germany) were performed which showed a centrally
located tumour, 90 mm in largest diameter, situated in segments IV, V,
VI & VIII. The tumour involved the right portal vein & right hepatic
artery and was closely related to the left hepatic artery (Fig. 1a). At a
2
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Fig. 3. On immunohistochemical staining the cells displayed HepPar1, CK7 and CD68 immunopositivity and immune-negativity for AFP.
Table 1
Included studies, patient and tumour characteristics.
Publication

Year

Country

Patients with FLC treated with TAA

Age (years)

Gender

Position of tumour

Tumour size (mm)*

Spence RA, et al. [34]
Wang Y, et al. [35]
Chang YC, et al. [36]
Czauderna P, et al. [37]
Hasiguchi M, et al. [38]
Eng J, et al. [39]
Mafeld S, et al. [40]
Polavarapu AD, et al. [41]
Current case

1987
1999
2003
2006
2013
2018
2018
2019
2020

South Africa
China
Taiwan
Poland
Japan
Malaysia
UK
USA
South Africa

1
5
1
1
1
1
1
1
1

19
NR
72
7
16
46
52
37
19

M
NR
M
F
F
F
F
M
F

Left liver
NR
Right liver
Bilateral and multifocal
Right liver
Right liver
Central (segments 1, 4a, 7, 8)
Left liver
Right liver

NR
NR
120
110
100
200
95
80
90

NR not reported *If multifocal – largest tumour size reported.
Table 2
Therapeutic interventions and results.
Authors
Spence RA, et al.
[34]
Wang Y, et al. [35]

Intent

Type of TAE

Surgical resection

Response

Survival

Radiological

Histological

Palliative

Lipiodol, doxorubicin, gelfoam

NA

Yes

NA

Palliative (1)

Lipodol

No

Yes

NR

4 – no detail

Yes

NR

Downsizing
(4)
Palliative

Lipiodol and doxorubicin, gelfoam

NA

NR

NA

Downsizing

Lipiodol and doxorubicin + mitomycin, gelfoam

No

Yes

N/A

Downsizing

Lipiodol and epirubicin + mitomycin

Yes

Yes

Downsizing

Drug eluting beads, doxorubicin

NR

NR

Mafeld S, et al. [40]

Downsizing

Yes

Yes

Polavarapu AD,
et al. [41]
Current case

Bleeding
control
Downsizing

Drug eluting beads, doxorubicin followed by
trans arterial radio-embolisation
Gelfoam

Extended right hemihepatectomy
Extended right hemihepatectomy
Extended left hemihepatectomy
Left hemi-hepatectomy

Yes

Yes

Extended right
hemihepatectomy

Yes

Yes

Chang YC, et al.
[36]
Czauderna P, et al.
[37]
Hasiguchi M, et al.
[38]
Eng J, et al. [39]

Drug eluting beads, doxorubicin

multidisciplinary team meeting an extended right hepatectomy was
recommended. Due to concern of the close relationship of the tumour to
the left portal structures a TACE using drug eluting beads was recom
mended. Following the TACE she developed a transient post

38 months at time of
publication
Median survival 25
months
5-year survival 25%
24 months at time of
publication
Died from TACE
complication
63 months at time of
publication
24 months at time of
publication
2 months at time of
publication
NR
18 months at time of
publication

embolectomy syndrome and a liver abscess that was treated with
percutaneous aspiration and antibiotics. A follow-up CE-CT scan three
months after the TACE confirmed response (Fig. 1b & c). An extended
right-sided hemi-hepatectomy was performed and the postoperative
3
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Fig. 4. Suggested treatment algorithm (*ideally as part of a clinical trial).

We propose an algorithm for the treatment of FLC (Fig. 4) which
includes TAE. Patients with clearly resectable disease should have a
surgical resection. Trans-arterial embolisation can be used to facilitate
surgical resection in patients with large tumours. Volume manipulation
such as portal vein embolization may be required in some patients to
ensure an adequate functional liver remnant. Patients with irresectable
disease confined to the liver should be considered for transplant. TAE
can also be used as a palliative modality if the disease is confined to the
liver. There are a number of new immuno-therapies targeting the
DNAJB1-PRKACA oncogene that are currently being investigated [3].
The role of systemic therapy remains unclear and regardless of indica
tion should preferably be used in the setting of clinical trials.

course was uneventful. The surgery was performed by an experienced
consultant HPB surgeon assisted by two fellows. The patient was dis
charged on post-operative day seven. Histology showed findings typical
for FLC with evidence of tumour necrosis related to the previous TACE
(Figs. 2 and 3). The patient is recurrence free 18 months after the
procedure.
3. Discussion
The literature review identified seven case reports and one case se
ries of patients with FLC treated with TAE) [10–17]. We included this
case report in the analysis (Tables 1 & 2). Details of the literature review
can be found in the attached supplementary material.
Treatments used for HCC, including resection, liver transplantation
and TAE have been extended to FLC with little supporting evidence.
There are no guidelines for resection of FLC, but in general patients
would be considered as candidates for resection if there is no evidence of
extrahepatic disease and the tumour is macroscopically resectable with
preservation of a sufficient future liver remanent. Five-year survival
rates ranging from 28 to 76% following surgical resection have been
reported for FLC [18–20]. Extensive resections are often possible due to
the younger age of patients and the absence of underlying liver disease.
These factors may account for the better outcomes reported compared to
patients with HCC, rather than the previously hypothesized more
indolent behaviour of FLC. Five-year survival rates following liver
transplantation of 43–55% have been reported which is worse than
transplantation for HCC within most criteria [5,6,18]. This discrepancy
may be due to more advanced FLC tumours being transplanted, but a
more aggressive tumour biology, possibly aggravated by posttransplantation immunosuppression cannot be excluded.
Conceptually TAE such as TACE and TARE are attractive, as similar
to HCC, FLCs are generally hypervascular. As opposed to HCC, where the
value of TAE has been established and its role is well defined, the benefit
and indications in FLC are less clear. Trans-arterial embolisation causes
selective tumour necrosis by disrupting the arterial supply to the
tumour. Due to the dual arterial and portal venous blood supply, ne
crosis of the surrounding liver parenchyma is rare. The tumour necrosis
caused by arterial deprivation is augmented by high concentrations of
chemotherapeutic agent in TACE and localised radiation in TARE. In the
majority of studies reporting on TAE in FLC the indication was for
downsizing tumours to facilitate resection [10–17].

4. Conclusion
Due to the rarity of the tumour, evidence on optimal management is
limited. Trans arterial therapies such as TACE and TARE may have a role
in the management of patients with FLC. Registries, preferably inter
national, would allow for larger patient cohorts in whom the role of not
only TAE but also systemic therapies in neo-adjuvant, adjuvant and
palliative settings can be assessed.
Consent
Written informed consent was obtained from the patient for publi
cation of this case report and accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this
journal on request.
Ethical approval
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by the Human Research Ethics Committee of the University of Cape
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